Dimension Capital I Update
Quarterly Letters
Portfolio
Automata
Modular hardware/software solution for lab automation
Mostafa Elsayed
Board Director
AP Moller, Hummingbird VC, Octopus Ventures
Continue to expand sales and deployments, with an emphasis on US market
Invest in product and engineering, expand scope of software to protocol versioning and data handling
Build out flagship deployments across core user segments: Pharma, biotech, diagnostics, CRO, CDMO
NewLimit
Developing epigenetic reprogramming medicines
Brian Armstrong
Jacob Kimmel
Greg Johnson
Blake Byers
Board Director
Founders Fund, Kleiner Perkins, Elad Gil
Functional rejuvenation (invitro) of human T-cells
Prove machine learning tractability of epigenetic space
Initiate biotech and pharma partnership conversations
Kimia Therapeutics
Rapid synthesis and screening of target-focused chemical libraries for drug discovery
Stig Hansen
Board Director
The Column Group
Establish automated platform to scale prior technology
Build out computational team, and hire key executives CSO and CTO
Initiate and progress multiple drug discovery campaigns
Enveda Biosciences
Small molecule discovery platform, sequencing the planet's chemistry
Viswa Colluru
Board Director
Kinnevik, FPV Capital, Allen & Co, Henry Kravis, True Ventures
Two assets dosing humans in Ph1 clinical trials against board approved targets and clinical plans
Another two assets in IND enabling studies against board approved targets with tractable clinical plans
Key hires at CFO and CSO positions
Lamin
Data infrastructure for R&D teams of any size
Alex Wolf
Sunny Sun
N/A
Pillar VC, Y Combinator
Product iteration and development progress towards product launch
Quality of high-signal users engaged with the product
Hiring and onboarding key engineering talent
Kaleidoscope Bio
Workflow Collaboration software for R&D teams
Bogdan Knezevic
Ahmed Elnaiem
David Yen
N/A
Hummingbird VC, Caffeinated Capital, SV Angel
Commercial engagement with customers (pilots, trials and executed contracts)
Product iteration and development progress
Team build and hiring key talent
Stately Bio
Computer vision and automation tech applied to cell differentiation
Frank Li
N/A
Caffeinated Capital
Commercial engagement with customers (pilots, trials and executed contracts)
Product iteration and development progress
Team build and hiring key talent
Exthymic
Distributed manufacturing for cell therapy
Rich Stoner
N/A
N/A
Raise Seed financing
Product iteration and development progress
Demonstrate early proof-of-concept of technology
FiveOneFour
Infra tool for data engineers
Tim
Delisle
Chris
Crane
Nic
Joseph
Board Director
N/A
Build the founding team
Launch open source software and engage the relevant engineering community
Early conversations and pilot engagements with customers
Chai Discovery
Joshua Meier
N/A
N/A
Raise Seed financing
Build the founding ML engineering team
Execute on 3-4 partnerships for data sharing and product platform building
Portfolio
Automata
Modular hardware/software solution for lab automation
Mostafa Elsayed
Board Director
AP Moller, Hummingbird VC, Octopus Ventures
Continue to expand sales and deployments, with an emphasis on US market
Invest in product and engineering, expand scope of software to protocol versioning and data handling
Build out flagship deployments across core user segments: Pharma, biotech, diagnostics, CRO, CDMO
NewLimit
Developing epigenetic reprogramming medicines
Brian Armstrong
Jacob Kimmel
Greg Johnson
Blake Byers
Board Director
Founders Fund, Kleiner Perkins, Elad Gil
Functional rejuvenation (invitro) of human T-cells
Prove machine learning tractability of epigenetic space
Initiate biotech and pharma partnership conversations
Kimia Therapeutics
Rapid synthesis and screening of target-focused chemical libraries for drug discovery
Stig Hansen
Board Director
The Column Group
Establish automated platform to scale prior technology
Build out computational team, and hire key executives CSO and CTO
Initiate and progress multiple drug discovery campaigns
Enveda Biosciences
Small molecule discovery platform, sequencing the planet's chemistry
Viswa Colluru
Board Director
Kinnevik, FPV Capital, Allen & Co, Henry Kravis, True Ventures
Two assets dosing humans in Ph1 clinical trials against board approved targets and clinical plans
Another two assets in IND enabling studies against board approved targets with tractable clinical plans
Key hires at CFO and CSO positions
Lamin
Data infrastructure for R&D teams of any size
Alex Wolf
Sunny Sun
N/A
Pillar VC, Y Combinator
Product iteration and development progress towards product launch
Quality of high-signal users engaged with the product
Hiring and onboarding key engineering talent
Kaleidoscope Bio
Workflow collaboration software for R&D teams
Bogdan Knezevic
Ahmed Elnaiem
David Yen
N/A
Hummingbird VC, Caffeinated Capital, SV Angel
Commercial engagement with customers (pilots, trials and executed contracts)
Product iteration and development progress
Team build and hiring key talent
Stately Bio
Computer vision and automation tech applied to cell differentiation
Frank Li
N/A
Caffeinated Capital
Commercial engagement with customers (pilots, trials and executed contracts)
Product iteration and development progress
Team build and hiring key talent
Exthymic
Distributed manufacturing for cell therapy
Rich Stoner
N/A
N/A
Raise Seed financing
Product iteration and development progress
Demonstrate early proof-of-concept of technology
FiveOneFour
Infra tool for data engineers
Tim
Delisle
Chris
Crane
Nic
Joseph
Board Director
Flybridge
Build the founding team
Launch open source software and engage the relevant engineering community
Early conversations and pilot engagements with customers
Chai Discovery
Generative AI for biology
Joshua Meier
N/A
N/A
Raise Seed financing
Build the founding ML engineering team
Execute on 3-4 partnerships for data sharing and product platform building
Research
NeurIPs (Neural Information Processing Systems) is the leading machine learning and computational neuroscience conference held every December with over 16,000 attendees, consisting of the world's top AI researchers and practitioners. See Dimension’s recap of the conference below and with more at our Research Substack
Our Portfolio
Community
.webp)
